W038

W038 is a novel, functionalized β-lactam small molecule currently in preclinical development for the treatment of cutaneous melanoma. Identified through diversity-oriented synthesis, W038 acts as a multi-target inhibitor that downregulates key signaling nodes within the MAPK, PI3K, and JAK/STAT pathways. In vitro studies demonstrate that the compound exhibits potent cytotoxicity against human and murine melanoma cell lines, significantly reduces colony formation, and inhibits cell migration. Its anti-tumor activity is further characterized by the disruption of redox homeostasis and the induction of apoptosis through the activation of caspase-3 and caspase-7. Pharmacokinetic predictions suggest that W038 possesses favorable drug-like properties, including high skin permeability and good oral bioavailability, supporting its potential for both topical and systemic administration.